These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 27491279

  • 1. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
    Tebboth A, Lee S, Scowcroft A, Bingham-Gardiner P, Spencer W, Bolodeoku J, Hassan SW.
    Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
    [Abstract] [Full Text] [Related]

  • 2. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
    Huang H, Shetty S, Bauer E, Lang K.
    Curr Med Res Opin; 2018 Jun; 34(6):1021-1027. PubMed ID: 29231750
    [Abstract] [Full Text] [Related]

  • 3. Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Ramirez G, Morrison AD, Bittle PA.
    Endocr Pract; 2013 Jun; 19(6):1025-34. PubMed ID: 23757605
    [Abstract] [Full Text] [Related]

  • 4. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
    Gibbs JP, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL, Gibbs MA.
    J Clin Pharmacol; 2012 Oct; 52(10):1494-505. PubMed ID: 22162539
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ.
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
    Lin WQ, Cai ZJ, Chen T, Liu MB, Li N, Zheng B.
    Front Endocrinol (Lausanne); 2021 Aug; 12():684960. PubMed ID: 34484112
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
    Takayanagi R, Uchida T, Kimura K, Yamada Y.
    Biol Pharm Bull; 2018 Aug; 41(2):153-157. PubMed ID: 29386477
    [Abstract] [Full Text] [Related]

  • 9. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P.
    Clin Ther; 2014 Dec 01; 36(12):2072-2079. PubMed ID: 25453730
    [Abstract] [Full Text] [Related]

  • 10. DPP-4 inhibitors: what may be the clinical differentiators?
    Gerich J.
    Diabetes Res Clin Pract; 2010 Nov 01; 90(2):131-40. PubMed ID: 20708812
    [Abstract] [Full Text] [Related]

  • 11. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
    Kostev K, Schokker E, Jacob L.
    Int J Clin Pharmacol Ther; 2018 Sep 01; 56(9):411-416. PubMed ID: 30049306
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
    Gilibili RR, Bhamidipati RK, Mullangi R, Srinivas NR.
    J Pharm Pharm Sci; 2015 Sep 01; 18(3):434-48. PubMed ID: 26517136
    [Abstract] [Full Text] [Related]

  • 14. DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice.
    Spanopoulos D, Busse M, Webb J, Tebboth A, Gollop ND, Marcus MW.
    Clin Ther; 2019 Aug 01; 41(8):1622-1630. PubMed ID: 31164243
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
    Park SH, Nam JY, Han E, Lee YH, Lee BW, Kim BS, Cha BS, Kim CS, Kang ES.
    Medicine (Baltimore); 2016 Aug 01; 95(32):e4543. PubMed ID: 27512877
    [Abstract] [Full Text] [Related]

  • 17. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
    Kaneko M, Narukawa M.
    Ann Pharmacother; 2017 Jul 01; 51(7):570-576. PubMed ID: 28622738
    [Abstract] [Full Text] [Related]

  • 18. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O, Kahle M, Deacon CF, Holst JJ, Nauck MA.
    Diabetes Obes Metab; 2016 Nov 01; 18(11):1100-1109. PubMed ID: 27300579
    [Abstract] [Full Text] [Related]

  • 19. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
    Kothny W, Lukashevich V, Foley JE, Rendell MS, Schweizer A.
    Diabetologia; 2015 Sep 01; 58(9):2020-6. PubMed ID: 26067186
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
    Baksh SN, McAdams-DeMarco M, Segal JB, Alexander GC.
    Pharmacoepidemiol Drug Saf; 2018 Jun 01; 27(6):660-667. PubMed ID: 29655237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.